XML 42 R25.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION

12 Months Ended

Dec. 31, 2020

STOCK-BASED COMPENSATION.

STOCK-BASED COMPENSATION

NOTE 18. STOCK-BASED COMPENSATION

As of December 31, 2020, we had two active stock-based incentive compensation plan: the 2017 Omnibus Incentive Plan and the Employee Stock Purchase Plan ("ESPP"). All new equity compensation grants are issued under these two plans; however, outstanding awards previously issued under inactive plans will continue to vest and remain exercisable in accordance with the terms of the respective plans. Our stock plans are administered by the Board of Directors Compensation Committee. On December 31, 2020, there were 3.0 million shares reserved and 2.3 million shares available for future grant under our stock-based incentive plans.

On May 4, 2017, the stockholders approved the Company’s 2017 Omnibus Incentive Plan ("the 2017 Plan") and all shares that were then available for issuance under the 2008 Omnibus Incentive Plan are now available for issuance under the 2017 Plan. The 2017 Plan and 2008 Plan provide for the grant of stock options, stock appreciation rights, restricted stock, stock units (including deferred stock units), unrestricted stock, and dividend equivalent rights. Any of the awards issued may be issued as performance-based awards to align stock compensation awards to the attainment of annual or long-term performance goals. As of December 31, 2020, there were 2.1 million shares available for grant under the 2017 Plan.

The Company grants restricted stock units and performance stock units. The grant date fair values of restricted stock units and performance stock units are based on the closing market price of our common stock on the grant date. Our restricted stock units vest based on continued service. Our performance stock units vest based on achievement of certain performance goals and certification of performance achievement by the Compensation Committee of the Board of Directors. Stock-based compensation expense, net of forfeitures, is recognized on a straight-line basis over the requisite service period. For performance stock units, compensation expense is updated for the Company’s expected performance level against performance goals at the end of each reporting period, which involves judgment as to achievement of certain performance metrics.

Stock-based Compensation Expense

We recognize stock-based compensation expense based on the fair value of the awards issued and the functional area of the employee receiving the award. Stock-based compensation was as follows:


		Years Ended December 31,
		2020			2019			2018
Stock-based compensation expense		$	12,272		$	7,327		$	9,703

Our stock-based compensation expense is based on the value of the portion of share-based payment awards that are ultimately expected to vest, assuming estimated forfeitures at the time of grant. Estimated forfeiture rates for our stock-based compensation expense applicable to stock options and restricted stock units ("RSU’s") were approximately 5%, 10% and 10% for the years ended December 31, 2020, 2019 and 2018, respectively.

Restricted Stock Units

The fair value of our RSUs is determined based upon the closing fair market value of our common stock on the grant date. Changes in the unvested RSUs were as follows:


		2020
				Weighted-
				Average
				Grant
		Shares		Value
RSUs outstanding at beginning of period		534		$	56.56
RSUs granted		342			59.51
RSUs vested		(152)			57.14
RSUs forfeited		(116)			58.10
RSUs outstanding at end of period		608		$	58.15

The total intrinsic value of RSUs converted to shares for the years ended December 31, 2020, 2019 and 2018 were $9.2 million, $8.3 million, and $13.6 million, respectively. As of December 31, 2020, there was $7.8 million of total unrecognized compensation cost, net of expected forfeitures related to non-vested RSUs granted, which is expected to be recognized through November 2023, with a weighted-average remaining vesting period of 1.0 years.

Stock Options

Stock option awards are generally granted with an exercise price equal to the market price of our stock at the date of grant and with either a three or four-year vesting schedule or performance-based vesting as determined at the time of grant. Stock option awards generally have a term of ten years.

Changes in our outstanding stock options were as follows:


		2020
				Weighted-
				Average
				Exercise
		Shares		Price
Options outstanding at beginning of period		185		$	21.56
Options exercised		(33)			13.43
Options forfeited		—			—
Options expired		(5)			15.43
Options outstanding at end of period		147		$	23.63

The total intrinsic value of options exercised for the years ended December 31, 2020, 2019 and 2018 was $1.9 million, $1.6 million and $4.1 million, respectively. All options outstanding on December 31, 2020 are vested and have aggregate intrinsic value of $10.8 million and weighted-average remaining contractual life of 3.9 years.

The following table summarizes information about the stock options outstanding on December 31, 2020:


		Options Outstanding and Exercisable
				Weighted-Average		Weighted-
		Number		Remaining		Average
Range of Exercise Prices		Outstanding		Contractual Life		Exercise Price
$9.51 to $12.44		5		0.67 years		$	11.18
$18.77		43		3.75 years			18.77
$26.32		99		4.10 years			26.32
$9.51 to $26.32		147		3.89 years		$	23.63

Employee Stock Purchase Plan

The ESPP, a stockholder-approved plan, provides for the issuance of rights to purchase up to 1,000,000 shares of common stock. In May 2010, stockholders approved an increase from 500,000 to 1,000,000 shares authorized for sale under our ESPP. Employees below the Vice President level are eligible to participate in the ESPP if employed by us for at least 20 hours per week during at least five months per calendar year. Participating employees may contribute up to the lesser of 15% of their eligible earnings or $5,000 during each plan period. Currently, the plan period is six months. The purchase price of common stock purchased under the ESPP is currently equal to the lower of 1) 85% of the fair market value of our common stock on the commencement date of each plan period or 2) 85% of the fair market value of our common shares on each plan period purchase date. On December 31, 2020, 0.2 million shares remained available for future issuance under the ESPP.

Purchase rights granted under the ESPP are valued using the Black-Scholes-Merton model. As of December 31, 2020, there was $0.4 million of total unrecognized compensation cost related to the ESPP that is expected to be recognized over a remaining period of five months. Total compensation expense was $0.9 million for the year ended December 31, 2020 and $0.5 million for the year ended December 31, 2019, and $0.4 million for the year ended December 31, 2018.

The fair value of each purchase right granted under the ESPP was estimated on the date of grant using the Black-Scholes-Merton option pricing model with the following assumptions:


		Years Ended December 31,
		2020		2019		2018
Risk-free interest rates		0.10% - 0.18%	%	1.62% - 2.31	%	2.10% - 2.56	%
Expected dividend yield rates		—	%	—	%	—	%
Expected term		0.5 years		0.5 years		0.5 years
Expected volatility		70.1	%	41.3	%	38.0	%

The risk-free interest rate is based on the six-month U.S. Treasury Bill at the time of the grant. We utilize our historical experience in determining the expected term of our stock options and volatility of our common stock. We have not historically issued dividends.